News

At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share.

Ad hoc announcement pursuant to Art. 53 LR

Robust performance in challenging market environment

medmix Switzerland AG has been named a winner in the 2024 BIG Sustainability Awards presented by the Business Intelligence Group. This achievement complements the company's BIG Innovation Award in January 2024 for its MIXPAC™ greenLine™ 400 mL 1:1 two-component cartridge set.

Ad hoc announcement pursuant to Art. 53 LR

First half broadly in line with expectations, with Dental recovery on track
Full-year 2024 guidance reduced to reflect ongoing softness in end markets

medmix asserts trademark rights to protect quality and consumer safety

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders.

COX Handheld Dispensers for One and Two-Component Materials: PC COX legacy since 1958 inherited by medmix Switzerland Ltd.

medmix' Drug Delivery (“Haselmeier”) and NIPRO CORPORATION (“Nipro”) announce an exclusive promotion and distribution partnership for PiccoJect™ in the Japanese market.

Ad hoc announcement pursuant to Art. 53 LR

medmix appoints René Willi as new Chief Executive Officer
medmix announces the appointment of René Willi as its new CEO, effective June 1, 2024.
Current CEO Girts Cimermans will be stepping down as of today.

Legal prohibition impacting Kettenbach/Xinial customers further clarified

Kettenbach/Xinial legally prevented from manufacture or offer for sale in Germany
Kettenbach/Xinial legally compelled to recall and destroy infringing system
medmix Switzerland Ltd. continues to enforce its rights

Ad hoc announcement pursuant to Art. 53 LR

Full-year 2023 revenue growth and profitability within communicated range
Improving trends expected throughout full-year 2024